Furthermore, utilizing the allosteric inhibitor ND-646, which specifically targets ACC1 and ACC2, led to a decrease in tumor growth in Kras/p53-/- and Kras/Stk11-/- mouse models of non-small-cell lung cancer. This evidence concerns the gene KRAS and non-small cell lung carcinoma.